- Most low-dose, local vaginal estrogen treatments for dryness do not require progesterone, even if you have a uterus.
- A major exception is Femring, which can act like systemic estrogen. If you have a uterus, you usually need uterine protection.
- HRT and the heart is not one-size-fits-all. Timing since menopause, age, and cardiovascular risk drive decision-making.
- In 2025 to 2026, regulators and medical leaders pushed for clearer hormone therapy labeling to better reflect individual risk and timing. See the FDA update here: FDA-approved labeling changes for menopausal hormone therapy products.
- If you want a personalized plan, you can book a telemedicine consultation here.
Why vaginal dryness deserves real attention
Vaginal dryness is not just “less lubrication.” For many women, it is part of genitourinary syndrome of menopause (GSM), which can include dryness, burning, irritation, recurrent urinary tract infections, bladder urgency, and pain with sex. GSM is common, often under-treated, and very responsive to the right therapy when we match treatment to symptoms and goals.
If your main concern is dryness, discomfort, or painful sex, local therapy may be enough. If you also have hot flashes, night sweats, sleep disruption, or mood changes, you may need to discuss systemic options and your risk profile.
If you want a tailored approach, you can book a telemedicine consultation here.
Q1: “I’m using vaginal estradiol for vaginal dryness. Do I need progesterone to protect my uterus?”
In most cases, no. If your vaginal estradiol is a low-dose, localized treatment intended primarily for vaginal and nearby urinary tissues, progesterone is generally not required, even if you still have your uterus.
The reason is simple. Low-dose local vaginal estrogen typically results in minimal systemic absorption and is intended to work mainly at the tissue level where symptoms occur.
Common examples of localized vaginal estrogen for dryness
- Vaginal estradiol inserts or tablets (Vagifem-type options)
- Vaginal estradiol softgel inserts (Imvexxy-type options)
- Vaginal estrogen creams (Estrace-type or Premarin-type options)
- Low-dose vaginal estrogen ring (Estring-type options)
Non-estrogen options that also usually do not require progesterone
- Vaginal DHEA (prasterone, Intrarosa-type)
- Oral ospemifene (Osphena-type)
For many women, these options provide meaningful relief without the need to add uterine protection. Your dose, your product, and your symptoms matter.
If you are not sure which product you are using, do not guess. Bring the medication name and dose to your next visit or share it during a telemedicine consultation: book a telemedicine consultation here.
The key exception: Femring is placed vaginally but can be systemic
The most important exception to “vaginal means local” is Femring. Femring is inserted vaginally, but it can deliver estrogen at systemic levels, meaning estrogen circulates throughout the body.
If you have a uterus and you use systemic estrogen, uterine protection is usually needed to reduce the risk of endometrial overgrowth. If you have any unexpected bleeding, that needs evaluation.
If you want a quick fact-check on current regulatory language around menopausal hormone therapy labeling, the FDA has a clear summary here: FDA requests labeling changes to clarify benefit-risk considerations.
Table 1: Do you need progesterone with vaginal therapy?
| Therapy type | Examples | Primary goal | Systemic exposure | Progesterone needed if uterus present?* |
| Low-dose local vaginal estrogen | Inserts/tablets, creams, low-dose local ring | GSM symptoms like dryness and painful sex | Usually low | Usually No |
| Vaginal DHEA (prasterone) | Intrarosa-type | GSM symptoms | Low systemic effect | Usually No |
| Oral ospemifene (SERM) | Osphena-type | Pain with sex (dyspareunia) | Systemic, non-estrogen | Usually No |
| Systemic estrogen vaginal ring | Femring | Hot flashes plus GSM | Higher, systemic | Usually Yes |
| Systemic estrogen (patch, gel, spray, pill) | Estradiol patch and other systemic forms | Hot flashes, night sweats, sleep disruption | Systemic | Usually Yes |
*General education only. Your history matters, including fibroids, bleeding history, clot risk, breast cancer risk, and medications.
Q2: “My doctor says hormone therapy (HT) increases stroke or heart attack risk. My friend is on HT and feels amazing . What should I do?”
First, it helps to separate two different topics: symptom relief and long-term disease prevention.
Hormone therapy is the most effective treatment for:
- Hot flashes and night sweats
- Sleep disruption related to vasomotor symptoms
- Many GSM symptoms, especially when local therapy is not enough
- Bone loss prevention in appropriate candidates
But heart risk messaging has been confusing for decades because many headlines ignore what clinicians call the timing concept. In plain language, the risk profile depends on how far you are from menopause and what your cardiovascular health looks like now.
A strong, current, globally recognized update on this topic is the 2024 International Menopause Society white paper: International Menopause Society White Paper on Menopause and MHT.
The heart disease question: what “timing” means in real life?
Here is the practical framework I use with patients.
Many women are better candidates when:
- They are younger than 60, or
- They are within about 10 years of their final menstrual period, and
- They do not have known cardiovascular disease or major contraindications
We slow down and evaluate more carefully when:
- They are older than 60, or
- They are more than about 10 years from menopause, or
- They have multiple cardiovascular risk factors or known vascular disease
This does not automatically mean “no hormone therapy.” It means the plan needs to be individualized and sometimes requires additional evaluation.
A recent guideline-level publication that reflects this individualized approach is the European Society of Endocrinology clinical practice guideline (2025): European Society of Endocrinology guideline for evaluation and management of menopause and perimenopause.
Table 2: A simple HRT decision map for heart risk discussions
| Patient situation | Typical symptom pattern | What we focus on clinically | Common next step |
| Within about 10 years of menopause, no known CVD | Hot flashes, night sweats, sleep disruption, mood changes, GSM | Blood pressure, migraine history, clot history, smoking, diabetes, lipids | Discuss systemic options and route; personalize dose |
| More than about 10 years past menopause, or older than 60 | Persistent symptoms or late-onset symptoms | Baseline cardiovascular risk and signs of plaque burden | Consider additional evaluation and nonhormonal alternatives if needed |
| GSM only, minimal hot flashes | Dryness, painful sex, urinary symptoms | Local tissue goals and symptom response | Start with local vaginal therapy and reassess |
| Prior clot, stroke, estrogen-sensitive cancer, or high-risk history | Variable | Safety first, contraindications, specialist coordination | Nonhormonal options or local-only strategies when appropriate |
| Has a uterus and needs systemic estrogen | Hot flashes plus GSM | Endometrial protection strategy | Add uterine protection when indicated |
Things you should know before starting, stopping, or changing HRT
- The route matters. Patch, gel, spray, and pill can have different risk profiles for some women.
- The dose matters. The goal is the lowest effective dose that meets your symptom goals, then reassess periodically.
- If you still have a uterus and are using systemic estrogen, uterine protection with progesterone is usually required.
- Any postmenopausal bleeding needs evaluation. Do not self-adjust hormones and assume bleeding is “normal.”
- Headlines are not your medical history. Your blood pressure, diabetes status, lipid profile, smoking, migraine history, and family history drive real risk.
- Local vaginal therapy can be life-changing for GSM. Many women do not need systemic therapy if their main issue is vaginal dryness and painful sex.
- Shared decision-making is essential. The right plan is the one that fits your symptoms, goals, and risk profile.
If you want help making sense of your options, you can book a telemedicine consultation here.
A major 2026 update: hormone therapy labeling is being modernized
In early 2026, the FDA announced approved labeling changes for several menopausal hormone therapy products, following a broader effort initiated in late 2025 to better reflect modern evidence and benefit-risk considerations. This matters because many women still make decisions based on outdated summaries that did not distinguish risk by age, timing since menopause, or formulation.
You can read the FDA announcement here: FDA approves labeling changes to menopausal hormone therapy products.
What this means for you as a patient is not “everyone should take hormones.” It means your discussion should be based on current evidence, your individual risk, and the therapy type, not blanket fear.
FAQs about vaginal dryness, wetness, moisturizers, and lubricants
How to treat vaginal dryness?
The best treatment depends on whether your dryness is occasional or persistent, and whether it comes with burning, urinary symptoms, or pain with sex. A practical step-by-step approach looks like this:
- Start with a vaginal moisturizer used on a schedule (not just during sex). Many women use it 2 to 3 times per week.
- Use a lubricant for sex even if you use a moisturizer. Moisturizer supports tissue hydration over time, lubricant reduces friction in the moment.
- If symptoms persist, consider prescription options such as low-dose local vaginal estrogen or other therapies appropriate for GSM.
- Treat triggers such as fragranced soaps, harsh cleansers, douching, and perfumed wipes, which can worsen irritation.
- Get evaluated if you have bleeding, recurrent UTIs, new pain, or symptoms that do not improve.
If you want a clear medical overview of causes and treatments, see: Mayo Clinic guidance on vaginal dryness.
Why is my area down there so dry?
Common reasons include:
- Perimenopause or menopause hormone changes, which thin and dry vaginal tissues
- Breastfeeding or postpartum hormone shifts
- Medications that dry mucous membranes (some allergy meds, antidepressants, and acne therapies)
- Irritants such as scented soaps, bubble baths, douching, and some pads or liners
- Autoimmune and dermatologic conditions that can affect vulvar tissue
Dryness that is persistent, painful, or paired with burning or tearing is worth a focused discussion because it is often part of GSM and is very treatable.
What is the best vaginal moisturizer?
“Best” means the one you will use consistently and that does not irritate you. In general, look for a moisturizer that is:
- Fragrance-free and dye-free
- Designed for vaginal use (not body lotion)
- Comfortable for you, with no burning after application
Common ingredient styles include hyaluronic acid-based moisturizers and bioadhesive polymer-based moisturizers. If one burns or irritates, stop and switch. If you have recurrent infections, sensitivities, or persistent burning, choose products carefully and consider an evaluation before trialing multiple options.
How to increase female lubrication naturally?
A few non-prescription strategies can help, especially for mild dryness:
- Increase arousal time and reduce pressure to “perform,” since arousal is linked to natural lubrication
- Stay hydrated and address contributing factors like smoking or poorly controlled blood sugar
- Avoid irritants like scented cleansers and douching
- Pelvic floor physical therapy can help when pain, tension, or anxiety about pain is part of the picture
If dryness is driven by GSM, “natural” strategies often help, but many women still need targeted therapy to fully restore comfort.
What lubricant do gynecologists recommend?
Most gynecologists lean toward lubricants that minimize irritation and friction. A safe starting point is:
- Water-based, fragrance-free lubricants for general use
- Silicone-based lubricants for longer-lasting glide, especially helpful when dryness is significant or sex is painful
If you are prone to irritation, look for options labeled fragrance-free and gentle for sensitive skin. If you use condoms, check compatibility with the lubricant type. If lubricants burn, that is a sign to switch products and consider whether GSM or another condition is contributing.
If you want a personalized plan based on your symptoms, medical history, and what you have already tried, you can book a telemedicine consultation here.
When to contact your clinician promptly
Please seek medical care promptly if you experience:
- Any postmenopausal bleeding
- New chest pain, shortness of breath, one-sided leg swelling, or sudden severe headache
- New neurologic symptoms such as weakness, facial droop, or trouble speaking
- A new breast lump
- Severe pelvic pain
- Sudden worsening migraines, especially with aura
A simple prep list for your next appointment
To make your visit efficient, bring:
- Your age and best estimate of age at menopause (or last period)
- Your top 3 symptoms and how they affect daily life
- Whether you have a uterus (hysterectomy or not)
- Your personal history of blood clots, stroke, heart disease, migraine with aura, breast cancer
- Your family history of early heart disease and breast or ovarian cancer
- Your current medications and supplements
- Recent blood pressure readings and any labs you have (lipids, A1c)
If you would like a structured, personalized plan, I offer telemedicine consultations. You can book your telemedicine consultation here.
Book a telemedicine consultation with Dr. Diana Hoppe, MD
If you are tired of conflicting advice and want clarity on:
- Whether your vaginal therapy is truly local or systemic
- Whether you need progesterone and which type fits your goals
- How your cardiovascular risk and timing since menopause affect HRT choices
- What to do if hormones are not appropriate for you
